Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 37Colorectal Neoplasms 16Liver Neoplasms 10Biliary Tract Neoplasms 10Cholangiocarcinoma 7Pancreatic Neoplasms 6Adenocarcinoma Of Esophagus 6Stomach Neoplasms 5Diabetes Mellitus, Insulin-Dependent, 12 4Squamous Cell Carcinoma of Head and Neck 3Melanoma 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Gallbladder Neoplasms 2Esophageal Neoplasms 2Carcinoma, Renal Cell 2Uterine Cervical Neoplasms 1Unresectable Hepatocellular Carcinoma 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Cancer Non-resectable 1Microsatellite Instability 1

Interventions

Blood Specimen Collection 6Magnetic Resonance Spectroscopy 4Tenofovir 3Liver Transplantation 3Specimen Handling 2Sorafenib 2Simvastatin 2tremelimumab 1sonidegib 1sofosbuvir-velpatasvir drug combination 1peginterferon alfa-2a 1navitoclax 1maltodextrin 1hepatitis B hyperimmune globulin 1durvalumab 1contrast agent BR1 1bavituximab 1atezolizumab 1apixaban 1adefovir dipivoxil 1Viusid 1Vitamin D 1User-Centered Design 1Surveys and Questionnaires 1Sunitinib 1Spermine Synthase 1Sonazoid 1Sampling Studies 1Radiotherapy 1Radiofrequency Ablation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fibrosis × tremelimumab × Gastrointestinal × Clear all
NCT05027425 2026-05-06

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

University of Cincinnati

Phase 2 Terminated
8 enrolled 9 charts
Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular, Hypertension, Portal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡